Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Lake Street Capital

Analysts at Lake Street Capital started coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $45.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. Westpark Capital assumed coverage on Aligos Therapeutics in a report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Finally, Cantor Fitzgerald started coverage on shares of Aligos Therapeutics in a research note on Thursday, May 21st. They issued an “overweight” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Aligos Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Aligos Therapeutics Price Performance

ALGS opened at $5.60 on Thursday. Aligos Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $13.69. The firm’s fifty day moving average price is $6.76 and its two-hundred day moving average price is $7.88. The company has a market capitalization of $34.66 million, a P/E ratio of -0.64 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. On average, equities research analysts expect that Aligos Therapeutics will post -7.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. raised its stake in Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after buying an additional 9,000 shares during the period. Susquehanna International Group LLP acquired a new stake in Aligos Therapeutics during the 3rd quarter worth approximately $99,000. XTX Topco Ltd acquired a new stake in Aligos Therapeutics during the 2nd quarter worth approximately $100,000. HRT Financial LP acquired a new stake in Aligos Therapeutics during the 4th quarter worth approximately $106,000. Finally, DRW Securities LLC acquired a new stake in Aligos Therapeutics during the 4th quarter worth approximately $111,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.